Clinics in chest medicine
-
The term "interventional pulmonology" (IP) supersedes the previously used term "thoracic endoscopy," a change that reflects the evolution of a specialty devoted to performing highly sophisticated and technologically advanced procedures in the lungs and chest. Continuing advances in technology promise to further expand IP's diagnostic and therapeutic frontiers. However, standardized educational programs to train and test IP physicians will be essential to maintain a high standard of practice in the field.
-
Complex airway diseases represent a therapeutic challenge and require multidisciplinary input. Surgery remains the definitive modality. ⋯ However, it has limited use if lesions are located in the upper lobes or lung periphery, but significant technological advances allow for effective treatments using the flexible bronchoscope. Rigid and flexible bronchoscopes should be seen as complementary procedures and most cases require the use of both modalities.
-
Clinics in chest medicine · Jun 2013
ReviewImpact of antiretroviral therapy on lung immunology and inflammation.
Human immunodeficiency virus (HIV) infection causes profound changes in the lung compartment characterized by macrophage and lymphocyte activation, secretion of proinflammatory cytokines and chemokines, and accumulation of CD8 T cells in the alveolar space, leading to lymphocytic alveolitis. Because many of the changes seen in the lung can be attributed to the direct effect of HIV on immune cells, therapy to reduce the HIV burden should have significant beneficial effects. Indeed, antiretroviral therapy rapidly reduces the viral burden in the lung, number of CD8 T cells in the alveolar space, and amount of proinflammatory cytokines and chemokines in bronchoalveolar lavage.
-
Clinics in chest medicine · Jun 2013
ReviewHuman immunodeficiency virus-associated tuberculosis: update on prevention and treatment.
Tuberculosis (TB) is the leading cause of opportunistic infection and mortality among HIV-infected persons. Screening for symptoms of TB in people with HIV infection, use of isoniazid preventive therapy for those with latent TB infection, earlier diagnosis and treatment of active TB disease, and early initiation of antiretroviral therapy are essential for controlling the spread of TB. Treatment of HIV-related TB is complicated by overlapping drug toxicities and drug-drug interactions between antiretroviral therapy and anti-TB therapy and risk for development of immune reconstitution inflammatory disease. This review provides an overview of the prevention and treatment of TB in HIV-infected persons.
-
Clinics in chest medicine · Jun 2013
ReviewPneumocystis pneumonia associated with human immunodeficiency virus.
Pneumocystis pneumonia (PCP) is caused by the yeastlike fungus Pneumocystis. Despite the widespread availability of specific anti-Pneumocystis prophylaxis and of combination antiretroviral therapy (ART), PCP remains a common AIDS-defining presentation. PCP is increasingly recognized among persons living in Africa. ⋯ Trimethoprim-sulfamethoxazole remains the preferred first-line treatment regimen. In the era of ART, mortality from PCP is approximately 10% to 12%. The optimal time to start ART in a patient with PCP remains uncertain.